Psychopharmacology

, Volume 183, Issue 2, pp 181–189

Striatal dopamine transporter availability with [123I]β-CIT SPECT is unrelated to gender or menstrual cycle

  • Susan E. Best
  • Philip M. Sarrel
  • Robert T. Malison
  • Marc Laruelle
  • Sami S. Zoghbi
  • Ronald M. Baldwin
  • John P. Seibyl
  • Robert B. Innis
  • Christopher H. van Dyck
Original Investigation

Abstract

Objectives

The effect of gender and female menstrual cycle on human striatal dopamine transporters (DATs) was investigated with single-photon emission computed tomography (SPECT) using the ligand 2β-carbomethoxy-3β-(4-[123I]iodophenyl)tropane.

Methods

Ten female subjects aged 18–40 years (25.3±7.3 years) were scanned twice during the early follicular and the mid-luteal phases to detect any hormone-mediated changes in DAT availability in the striatum or serotonin transporter (SERT) availability in brainstem–diencephalon. Plasma estradiol and progesterone levels were obtained at the time of SPECT and confirmed the expected increases from the follicular to the luteal phases. Finally, in a post hoc analysis of a previously published healthy-subject sample, striatal DAT availability was compared between 70 male and 52 female subjects who ranged in age from 18 to 88 years.

Results

In the ten menstrual cycle subjects, DAT availability (V3″) in striatum and SERT availability in brainstem–diencephalon did not differ between follicular and luteal phases. Moreover, change in V3″ for striatum or brainstem–diencephalon was uncorrelated with change in plasma estradiol or progesterone from the follicular to the luteal phase. In the larger healthy-subject sample, there was no significant effect of gender or the interaction of age and gender on striatal V3″.

Conclusions

These findings suggest that in using DAT or SERT ligands in the study of neuropsychiatric disorders, matching of female subjects according to a menstrual cycle phase is unnecessary. Although the present investigation did not confirm previous reports of gender differences in striatal DAT availability, controlling for gender in such studies still seems advisable.

Keywords

[123I]β-CIT Dopamine transporter Serotonin transporter SPECT Gender Women Menstrual cycle 

References

  1. Allard P, Marcusson JO, Ross SB (1994) [3H]GBR-12935 binding to cytochrome P450 in the human brain. J Neurochem 62:342–348PubMedGoogle Scholar
  2. Andersen SL, Rutstein M, Benzo JM, Hostetter JC, Teicher MH (1997) Sex differences in dopamine receptor overproduction and elimination. Neuroreport 8:1495–1498PubMedCrossRefGoogle Scholar
  3. Boja JW, Patel A, Carroll FI, Rahman MA, Philip A, Lewin AH, Kopajtic TA, Kuhar MJ (1991) [125I]RTI-55: a potent ligand for dopamine transporters. Eur J Pharmacol 194:133–134CrossRefPubMedGoogle Scholar
  4. Bossé R, Rivest R, Di Paolo T (1997) Ovariectomy and estradiol treatment affect the dopamine transporter and its gene expression in the rat brain. Brain Res Mol Brain Res 46:343–346CrossRefPubMedGoogle Scholar
  5. Brady KT, Grice DE, Dustan Cl, Randall C (1993) Gender differences in substance use disorders. Am J Psychiatry 150:1707–1711PubMedGoogle Scholar
  6. Carroll FI, Rahman MA, Abraham P, Parham K, Lewin AH, Dannals RF, Shaya E, Scheffel U, Wong DF, Boja JW, Kuhar MJ (1991) [123I]3β-(4-iodophenyl)tropan-2β-carboxylic acid methyl ester (RTI-55), a unique cocaine receptor ligand for imaging the dopamine and serotonin transporters in vivo. Med Chem Res 1:289–294Google Scholar
  7. Cortes R, Soranoi E, Pazos A, Probst A, Palacios J (1988) Autoradiography of antidepressant binding sites in the human brain: localization using [3H]imipramine and [3H]paroxetine. Neuroscience 27:473–496CrossRefPubMedGoogle Scholar
  8. Di Paolo T (1994) Modulation of brain dopamine transmission by sex steroids. Rev Neurosci 5:27–42PubMedGoogle Scholar
  9. Farde L, Hall H, Pauli S, Halldin C (1995) Variability in D2-dopamine receptor density and affinity: a PET study with [11C]raclopride in man. Synapse 20:200–208CrossRefPubMedGoogle Scholar
  10. Folstein MF, Fostein SE, McHugh PR (1975) “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198CrossRefPubMedGoogle Scholar
  11. Gardiner SA, Morrison MF, Mozley PD, Mozley LH, Brensinger C, Bilker W, Newberg A, Battistini M (2004) Pilot study on the effect of estrogen replacement therapy on brain dopamine transporter availability in healthy, postmenopausal women. Am J Geriatr Psychiatry 12:621–630CrossRefPubMedGoogle Scholar
  12. Gunning-Dixon FM, Head D, McQuain J, Acker JD, Raz N (1998) Differential aging of the human striatum: a prospective MR imaging study. AJNR Am J Neuroradiol 19:1501–1507PubMedGoogle Scholar
  13. Heinz A, Ragan P, Jones DW, Hommer D, Williams W, Knable MB, Gorey JG, Doty L, Geyer C, Lee KS, Coppola R, Weinberger DR, Linnoila M (1998) Reduced central serotonin transporters in alcoholism. Am J Psychiatry 155:1544–1549PubMedGoogle Scholar
  14. Innis RB, Seibyl JP, Scanley BE, Laruelle M, Abi-Dargham A, Wallace E, Baldwin RM, Zea-Ponce Y, Zoghbi S, Wang S, Gao Y, Neumeyer JL, Charney DS, Hoffer PB, Marek KL (1993) Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci U S A 90:11965–11969PubMedCrossRefGoogle Scholar
  15. Jacobsen LK, Staley JK, Malison RT, Zoghbi SS, Seibyl JP, Kosten TR, Innis RB (2000) Elevated central serotonin transporter binding availability in acutely abstinent cocaine-dependent patients. Am J Psychiatry 157:1134–1140CrossRefPubMedGoogle Scholar
  16. Jernigan TL, Archibald SL, Berhow MT, Sowell ER, Foster DS, Hesselink JR (1991) Cerebral structure on MRI, Part I: localization of age-related changes. Biol Psychiatry 29:55–67CrossRefPubMedGoogle Scholar
  17. Kaasinen V, Nagren K, Hietala J, Farde L, Rinne JO (2001) Sex differences in extrastriatal dopamine d(2)-like receptors in the human brain. Am J Psychiatry 158:308–311CrossRefPubMedGoogle Scholar
  18. Kuikka JT, Tiihonen J, Karhu J, Bergström KA, Räsänen P (1997) Fractal analysis of striatal dopamine re-uptake sites. Eur J Nucl Med 24:1085–1090PubMedGoogle Scholar
  19. Kuopio AM, Marttila RJ, Helenius H, Rinne UK (1999) Changing epidemiology of Parkinson's disease in southwestern Finland. Neurology 52:302–308PubMedGoogle Scholar
  20. Laruelle M, Vanisberg M-A, Maloteaux J-M (1988) Regional and subcellular localization in human brain of [3H]paroxetine binding, a marker of serotonin uptake sites. Biol Psychiatry 24:299–309CrossRefPubMedGoogle Scholar
  21. Laruelle M, Baldwin RM, Malison RT, Zea-Ponce Y, Zoghbi SS, Al-Tikriti MS, Sybirska EH, Zimmermann R, Wisniewski G, Neumeyer JL, Milius RA, Wang S, Smith EO, Roth RH, Charney DS, Hoffer PB, Innis RB (1993) SPECT imaging of dopamine and serotonin transporters with [123I]β-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 13:295–309CrossRefPubMedGoogle Scholar
  22. Laruelle M, Wallace E, Seibyl JP, Baldwin RM, Zea-Ponce Y, Zoghbi SS, Neumeyer JL, Charney DS, Hoffer PB, Innis RB (1994) Graphical, kinetic, and equilibrium analyses of in vivo [123I]β-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 14:982–994PubMedGoogle Scholar
  23. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, De Souza C, Krystal JH, Seibyl JP, Baldwin RM, Innis RB (2000) Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [123I]β-CIT SPECT. Biol Psychiatry 47:371–379CrossRefPubMedGoogle Scholar
  24. Lavalaye J, Booij J, Reneman L, Habraken JBA, van Royen EA (2000) Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers. Eur J Nucl Med 27:867–869CrossRefPubMedGoogle Scholar
  25. Malison RT, McDougle CJ, van Dyck C, Scahill L, Baldwin RM, Price LH, Leckman JF, Innis RB (1995) [123I]β-CIT SPECT imaging demonstrates increased striatal dopamine transporter binding in Tourette's syndrome. Am J Psychiatry 152:1359–1361PubMedGoogle Scholar
  26. Malison RT, Best SE, van Dyck CH, McCance EF, Wallace EA, Laruelle M, Baldwin RM, Seibyl JP, Price LH, Kosten TR, Innis RB (1998a) Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [123I]β-CIT SPECT. Am J Psychiatry 155:832–834PubMedGoogle Scholar
  27. Malison RT, Price LH, Berman RM, van Dyck CH, Pelton GH, Carpenter LL, Sanacora G, Owens MJ, Nemeroff CB, Rajeevan N, Baldwin RM, Seibyl JP, Innis RB, Charney DS (1998b) Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry 44:1090–1098CrossRefPubMedGoogle Scholar
  28. Metcalf MG, Mackenzie JA (1980) Incidence of ovulation in young women. J Biosoc Sci:345–352Google Scholar
  29. Morissette M, Di Paolo T (1993) Sex and estrous cycle variations of rat striatal dopamine uptake sites. Neuroendocrinology 58:16–22PubMedCrossRefGoogle Scholar
  30. Mozley LH, Gur RC, Mozley PD, Gur RE (2001) Striatal dopamine transporters and cognitive functioning in healthy men and women. Am J Psychiatry 158:1492–1499CrossRefPubMedGoogle Scholar
  31. Murphy GM Jr (1985) The human corpus striatum and dentate nucleus: volumetric analysis for hemispheric asymmetries, sex differences, and aging changes. Exp Neurol 89:134–145CrossRefPubMedGoogle Scholar
  32. Neumeyer JL, Wang S, Milius RA, Baldwin RM, Zea-Ponce Y, Hoffer PB, Sybirska E, Al-Tikriti M, Charney DS, Malison RT, Laruelle MA, Innis RB (1991) [123I]-2-β-Carbomethoxy-3-β-(4-iodophenyl)-tropane (β-CIT): high affinity SPECT radiotracer of monoamine reuptake sites in brain. J Med Chem 34:3144–3146CrossRefPubMedGoogle Scholar
  33. Nördstrom A-L, Olsson H, Halldin C (1998) A PET study of D2 dopamine receptor density at different phases of the menstrual cycle. Psychiatry Res 83:1–6PubMedCrossRefGoogle Scholar
  34. Pohjalainen T, Rinne JO, Någren K, Syvälahti E, Hietala J (1998) Sex differences in the striatal dopamine D2 receptor binding characteristics in vivo. Am J Psychiatry 155:768–773PubMedGoogle Scholar
  35. Poirier M-F, Benkelfat C, Galzin A-M, Langer SZ (1986) Platelet 3H-imipramine binding and steroid hormones serum concentrations during the menstrual cycle. Psychopharmacology (Berl) 88:86–89CrossRefGoogle Scholar
  36. Rivest R, Falardeau P, Di Paolo T (1995) Brain dopamine transporter: gender differences and effect of chronic haloperidol. Brain Res 692:269–272CrossRefPubMedGoogle Scholar
  37. Rojansky N, Halbreich U, Zander K, Barkai A, Goldstein S (1991) Imipramine receptor binding and serotonin uptake in platelets of women with premenstrual changes. Gynecol Obstet Invest 31:146–152PubMedCrossRefGoogle Scholar
  38. Seeman MV (1982) Gender differences in schizophrenia. Can J Psychiatry 27:107–112PubMedGoogle Scholar
  39. Seeman MV (1996) The role of estrogen in schizophrenia. J Psychiatry Neurosci 21:123–127PubMedGoogle Scholar
  40. Seibyl JP, Wallace E, Smith EO, Stabin M, Baldwin RM, Zea-Ponce Y, Gao Y, Zhang YW, Neumeyer JL, Zubal IG, Charney DS, Hoffer PB, Innis RB (1994) Whole-body biodistribution, radiation absorbed dose, and brain SPECT imaging with iodine-123-β-CIT in healthy human subjects. J Nucl Med 35:764–770PubMedGoogle Scholar
  41. Seibyl JP, Marek KL, Quinlan D, Sheff K, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Fussell B, Smith EO, Charney DS, van Dyck CH, Hoffer PB, Innis RB (1995) Decreased single-photon emission computed tomographic [123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 38:589–598CrossRefPubMedGoogle Scholar
  42. Seibyl JP, Laruelle M, van Dyck CH, Wallace E, Baldwin RM, Zoghbi SS, Zea-Ponce Y, Neumeyer J, Charney DS, Hoffer PB, Innis RB (1996) Reproducibility of iodine-123-β-CIT SPECT brain measurement of dopamine transporters. J Nucl Med 37:222–228PubMedGoogle Scholar
  43. Sofuoglu M, Dudish-Poulsen S, Nelson D, Pentel PR, Hatsukami DK (1999) Sex and menstrual cycle differences in the subjective effects from smoked cocaine in humans. Exp Clin Psychopharmacol 7:274–283CrossRefPubMedGoogle Scholar
  44. Sorenson JA, Phelps ME (1987) Physics in nuclear medicine. Saunders, PhiladelphiaGoogle Scholar
  45. Soucy J-P, Mrini A, Lafaille F, Doucet G, Descarries L (1997) Comparative evaluation of [3H]WIN 35428 and [3H]GBR 12935 as markers of dopamine innervation density in brain. Synapse 25:163–175CrossRefPubMedGoogle Scholar
  46. Staley JK, Basile M, Flynn DD, Mash DC (1994) Visualizing dopamine and serotonin transporters in the human brain with the potent cocaine analogue [125I]RTI-55: in vitro binding and autoradiographic characterization. J Neurochem 62:549–555PubMedCrossRefGoogle Scholar
  47. Staley JK, Krishnan-Sarin S, Zoghbi SS, Tamagnan G, Fujita M, Seibyl JP, Maciejewski PK, O'Malley S, Innis RB (2001) Sex differences in [123I]β-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse 41:275–284CrossRefPubMedGoogle Scholar
  48. Steege JG, Stout AL, Knight DL, Nemeroff CB (1992) Reduced platelet tritium-labeled imipramine binding sites in women with premenstrual syndrome. Am J Obstet Gynecol 167:168–172PubMedGoogle Scholar
  49. Tiihonen J, Kuikka J, Bergström K, Hakola P, Karhu J, Ryynänen O-P, Föhr J (1995) Altered striatal dopamine re-uptake site densities in habitually violent and non-violent alcoholics. Nat Med 1:654–657CrossRefPubMedGoogle Scholar
  50. van Dyck CH, Seibyl JP, Malison RT, Wallace E, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Charney DS, Hoffer PB, Innis RB (1995) Age-related decline in dopamine transporter binding in human striatum with [123I]β-CIT SPECT. J Nucl Med 36:1175–1181PubMedGoogle Scholar
  51. van Dyck CH, Malison RT, Seibyl JP, Laruelle M, Klumpp H, Zoghbi SS, Baldwin RM, Innis RB (2000) Age-related decline in central serotonin transporter availability with [123I]β-CIT SPECT. Neurobiol Aging 21:497–501CrossRefPubMedGoogle Scholar
  52. van Dyck CH, Quinlan DM, Cretella LM, Staley JK, Malison RT, Baldwin RM, Seibyl JP, Innis RB (2002a) Unaltered dopamine transporter availability in adult attention deficit hyperactivity disorder. Am J Psychiatry 159:309–312CrossRefPubMedGoogle Scholar
  53. van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Zoghbi SS, Baldwin RM, Innis RB (2002b) Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry 10:36–43CrossRefPubMedGoogle Scholar
  54. Wong DF, Broussolle EP, Wand G, Villemagne V, Dannals RF, Links JM, Zacur HA, Harris J, Naidu S, Braestrup C, Wagner HN, Gjedde A (1988) In vivo measurement of dopamine receptors in human brain by positron emission tomography: age and sex differences. Ann N Y Acad Sci 515:203–214PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Susan E. Best
    • 1
  • Philip M. Sarrel
    • 2
  • Robert T. Malison
    • 1
  • Marc Laruelle
    • 1
    • 3
  • Sami S. Zoghbi
    • 4
  • Ronald M. Baldwin
    • 1
    • 3
  • John P. Seibyl
    • 1
    • 4
  • Robert B. Innis
    • 1
    • 3
  • Christopher H. van Dyck
    • 1
    • 3
    • 5
  1. 1.Department of PsychiatryYale University School of MedicineNew HavenUSA
  2. 2.Department of Obstetrics and GynecologyYale University School of MedicineNew HavenUSA
  3. 3.VA Connecticut Healthcare SystemNew HavenUSA
  4. 4.Department of Diagnostic RadiologyYale University School of MedicineNew HavenUSA
  5. 5.Department of NeurobiologyYale University School of MedicineWest HavenUSA

Personalised recommendations